

Spark Therapeutics, Inc.  
Form SC 14D9/A  
March 18, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**(Rule 14d-101)**

**(Amendment No. 1)**

**SOLICITATION/RECOMMENDATION STATEMENT**  
**UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Spark Therapeutics, Inc.**  
**(Name of Subject Company)**

**Spark Therapeutics, Inc.**  
**(Name of Person(s) Filing Statement)**

**COMMON STOCK, PAR VALUE \$0.001 PER SHARE**  
**(Title of Class of Securities)**

**84652J103**

**(CUSIP Number of Class of Securities)**

**Joseph W. La Barge**

**Chief Legal Officer**

**Spark Therapeutics, Inc.**

**3737 Market Street**

**Suite 1300**

**Philadelphia, Pennsylvania 19104**

**(888) 772-7560**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications  
on Behalf of the Person(s) Filing Statement)**

***With copies to:***

**Stuart M. Cable, Esq.**

**Lisa R. Haddad, Esq.**

**Blake Liggio, Esq.**

**Goodwin Procter LLP**

**100 Northern Avenue**

**Boston, Massachusetts 02210**

**(617) 570-1000**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.



This Amendment No. 1 (this *Amendment No. 1* ) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, the *Schedule 14D-9* ) filed by Spark Therapeutics, Inc., a Delaware corporation (the *Company*, *Spark*, *we* or *us* ), with the Securities and Exchange Commission (the *SEC* ) on March 7, 2019.

The Schedule 14D-9 relates to the cash tender offer (the *Offer* ) by 022019 Merger Subsidiary, Inc., a Delaware corporation ( *Merger Sub* ), a wholly owned subsidiary of Roche Holdings, Inc., a Delaware corporation ( *Roche Holdings* ), to acquire all of the issued and outstanding shares of common stock, par value \$0.001 per share (the *Shares* and each, a *Share* ), at a price per Share equal to \$114.50, net to the seller of such Shares in cash, without interest, subject to any withholding of taxes required by applicable law. The Offer is disclosed in the Tender Offer Statement on Schedule TO (together with any amendments or supplements thereto, the *Schedule TO* ), filed by Roche Holdings and Merger Sub with the SEC on March 7, 2019, and is made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated March 7, 2019 (together with any amendments or supplements thereto, the *Offer to Purchase* ), and in the related Letter of Transmittal.

The information in the Schedule 14D-9, including all exhibits and annexes that were previously filed with the Schedule 14D-9, is incorporated in this Amendment No. 1 by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein. Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Schedule 14D-9 and page number references herein refer to the Schedule 14D-9.

#### ***Item 8. Additional Information***

1. Item 8 of the Schedule 14D-9 is hereby amended and supplemented by inserting the following heading and paragraph on page 45 of the Schedule 14D-9, after the paragraph entitled *Annual and Quarterly Reports* :  
**Legal Proceedings Related to the Offer and the Merger.**

On March 7, 2019, a putative securities class action complaint, *Wang v. Spark Therapeutics, Inc. et al.*, No. 1:19-cv-00479 (the *Wang Complaint* ), was filed in the United States District Court for the District of Delaware by purported Spark shareholder Elaine Wang against Spark and Spark's directors in connection with the Transactions. On March 11, 2019, a putative securities class action complaint, *Kent v. Spark Therapeutics, Inc. et al.*, No. 1:19-cv-00485 (the *Kent Complaint* ), was filed in the United States District Court for the District of Delaware by purported Spark shareholder Michael Kent against Spark, Spark's directors, Merger Sub, and Roche Holdings in connection with the Transactions. On March 18, 2019, a putative securities class action complaint, *Newman v. Spark Therapeutics, Inc. et al.*, No. 1:19-cv-00528 (the *Newman Complaint* ), was filed in the United States District Court for the District of Delaware by purported Spark shareholder Arthur Newman against Spark and Spark's directors in connection with the Transactions. The Wang Complaint, the Kent Complaint and the Newman Complaint allege that the Schedule 14D-9 filed on March 7, 2019 in connection with the Transactions omitted certain supposedly material information. The Wang Complaint, the Kent Complaint, and the Newman Complaint assert claims against all the defendants for violation of Section 14(e) of the Exchange Act, and against Spark's directors, and in the case of the Kent Complaint, Roche Holdings, for violation of Section 20(a) of the Exchange Act. The Wang Complaint and the Kent Complaint also assert claims against all defendants for violation of Section 14(d) of the Exchange Act. The Wang Complaint, the Kent Complaint, and the Newman Complaint seek declaratory and injunctive relief, as well as damages and attorneys' fees and costs. The Company and the board of directors of the Company believe that the Wang Complaint, the Kent Complaint, and the Newman Complaint are without merit and the Company, the board of directors of the Company, Merger Sub, and Roche Holdings intend to defend vigorously against such claims. Additional similar cases may also be filed in connection with the Offer or the Merger.

2. The first paragraph set forth in Item 8 in the section titled *Regulatory Approvals* on page 44 of the Schedule 14D-9 is hereby amended and restated in its entirety and replaced by the paragraphs set forth below:

Under the HSR Act, certain acquisition transactions may not be consummated unless certain information has been furnished to the Antitrust Division of the Department of Justice (the *Antitrust Division*) and the Federal Trade Commission ( *FTC* ) in Notification and Report Forms provided by the acquiring and acquired persons, and certain waiting period requirements have been satisfied. The initial waiting period for a cash tender offer is 15 days, but (1) this period may be shortened if the reviewing agency grants early termination, (2) it may be restarted if the acquiring person voluntarily withdraws and re-files its Notification and Report Form (a *pull-and-refile* ), and/or (3) it may be extended if the reviewing agency issues a request for additional information and documentary material, in which case the waiting period expires 10 days after the date when the acquiring person has substantially complied with such request. The purchase of Shares pursuant to the Offer is subject to such requirements. The Company and Roche Holdings each filed a Premerger Notification and Report Form under the HSR Act with the FTC and the Antitrust Division in connection with the purchase of Shares in the Offer on March 1, 2019. The required waiting period with respect to the Offer was to expire at 11:59 p.m., Eastern Time on March 18, 2019. According to the Offer to Purchase, Roche Holdings has withdrawn the March 1, 2019 filing effective on March 18, 2019. Roche Holdings refiled a Premerger Notification and Report Form under the HSR Act with respect to the Offer and the Merger with the Antitrust Division and the FTC on March 18, 2019.

Following such refiling, the waiting period applicable to the purchase of Shares pursuant to the Offer will expire at 11:59 p.m., New York City time, on April 2, 2019, unless (a) the period is shortened and the transaction receives early termination, (b) the period is lengthened by a pull-and-refile, and/or (c) the period is lengthened by a reviewing agency that issues a request for additional information and documentary material. If such a request is made, the waiting period will be extended until 11:59 p.m., New York City time, on the date that is ten calendar days after substantial compliance by Roche Holdings with such request. Thereafter, such waiting period can be extended only by court order or agreement of the Company, Roche Holdings, Merger Sub and the Antitrust Division or the FTC, as applicable. It is also possible that the Company and Roche Holdings could enter into a timing agreement with the reviewing agency that could affect the timing of the closing of the transactions contemplated by the Merger Agreement. The Antitrust Division and the FTC assess the legality under the antitrust laws of transactions such as the acquisition of Shares by Merger Sub pursuant to the Offer. At any time before or after the consummation of any such transactions, the Antitrust Division or the FTC could take such action under the antitrust laws of the United States as it deems necessary or desirable in the public interest, including seeking to enjoin the purchase of Shares pursuant to the Offer or seeking divestiture of the Shares so acquired or divestiture of assets of Roche Holdings and/or the Company. Private parties and individual states of the United States may also bring legal actions under the antitrust laws of the United States. The Company does not believe that the consummation of the Offer will result in a violation of any applicable antitrust laws. However, there can be no assurance that a challenge to the Offer on antitrust grounds will not be made, or if such a challenge is made, what the result would be.

#### ***Item 9. Additional Information***

Item 9 of the Schedule 14D-9 is hereby amended and supplemented by adding the following Exhibits to the list of Exhibits:

<b>Exhibit No.</b>	<b>Description</b>
(a)(5)(F)	Complaint filed as of March 7, 2019 (Wang v. Spark Therapeutics, Inc., et al., Case No. 1:19-cv-00479) (incorporated by reference to Exhibit (a)(5)(x) to the Schedule TO).
(a)(5)(G)	Complaint filed as of March 11, 2019 (Kent v. Spark Therapeutics, Inc., et al., Case No. 1:19-cv-00485) (incorporated by reference to Exhibit (a)(5)(xi) to the Schedule TO).
(a)(5)(H)	Complaint filed as of March 18, 2019 (Newman v. Spark Therapeutics, Inc., et al., Case No. 1:19-cv-00528) incorporated by reference to Exhibit (a)(5)(xii) to the Schedule TO.

***SIGNATURE***

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 18, 2019

Spark Therapeutics, Inc.

By: /s/ Joseph W. La Barge  
Name: Joseph W. La Barge  
Title: Chief Legal Officer